Milea Timbergen

16 38 . Chugh R, Wathen JK, Patel SR, Maki RG, Meyers PA, Schuetze SM, et al. Efficacy of imatinib in aggressive fibromatosis: Results of a phase II multicenter Sarcoma Alliance for Research through Collaboration (SARC) trial. Clin Cancer Res. 2010;16(19):4884-4891. 39 . Penel N, Le Cesne A, Bui BN, Perol D, Brain EG, Ray-Coquard I, et al. Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): An FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up. Annals of Oncology. 2011;22(2):452-457. 40 . Kasper B, Gruenwald V, Reichardt P, Bauer S, Rauch G, Limprecht R, et al. Imatinib induces sustained progression arrest in RECIST progressive desmoid tumours: Final results of a phase II study of the German Interdisciplinary Sarcoma Group (GISG). Eur J Cancer. 2017;76:60-67. 41 . Gounder MM, Lefkowitz RA, Keohan ML, D’Adamo DR, Hameed M, Antonescu CR, et al. Activity of sorafenib against desmoid tumor/deep fibromatosis. Clinical Cancer Research. 2011;17(12):4082-4090. 42 . Gounder MM, Mahoney MR, Van Tine BA, Ravi V, Attia S, Deshpande HA, et al. Sorafenib for Advanced and Refractory Desmoid Tumors. N Engl J Med. 2018;379(25):2417-2428. 43 . Szucs Z, Messiou C, Wong HH, Hatcher H, Miah A, Zaidi S, et al. Pazopanib, a promising option for the treatment of aggressive fibromatosis. Anticancer Drugs. 2017;28(4):421-426. 44 . Toulmonde M, Laure Ray-Coquard I, Pulido M, Andre T, Isambert N, Chevreau C, et al. DESMOPAZ pazopanib (PZ) versus IV methotrexate/vinblastine (MV) in adult patients with progressive desmoid tumors (DT) a randomized phase II study from the French Sarcoma Group. J Clin Oncol. 2018;36:suppl; abstr 11501. 45 . Villalobos V. NCT03785964, Nirogacestat for Adults With Desmoid Tumor/ Aggressive Fibro- matosis (DT/AF) (DeFi). Clinical Trials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT03785964?term=PF-03084014&cond=desmoid&draw=2&rank=3. 46 . Kim HA, Koo BK, Cho JH, Kim YY, Seong J, Chang HJ, et al. Notch1 counteracts WNT/β-catenin signaling through chromatin modification in colorectal cancer. J Clin Invest. 2012;122(9):3248-3259. 47 . Messersmith WA, LoRusso P, Cleary JM, Dasari A, Zhang X, Shaik MN, et al. A phase I dose-escalation study of the novel gamma secretase inhibitor PF-03084014 in patients (pts) with advanced solid tumors. Journal of Clinical Oncology. 2011;29(15). 48 . Messersmith WA, Shapiro GI, Cleary JM, Jimeno A, Dasari A, Huang B, et al. A Phase I, dose-finding study in patients with advanced solid malignancies of the oral gamma-secretase inhibitor PF-03084014. Clin Cancer Res. 2015;21(1):60-67. 49 . Garvey PB, Booth JH, Baumann DP, Calhoun KA, Liu J, Pollock RE, et al. Complex reconstruction of desmoid tumor resections does not increase desmoid tumor recurrence. Journal of the American College of Surgeons. 2013;217(3):472-480. 50 . Colombo C, Miceli R, Lazar AJ, Perrone F, Pollock RE, Le Cesne A, et al. CTNNB1 45F mutation is a molecular prognosticator of increased postoperative primary desmoid tumor recurrence: an independent, multicenter validation study. Cancer. 2013;119(20):3696-3702. 51 . van Broekhoven DL, Verhoef C, Grunhagen DJ, van Gorp JM, den Bakker MA, Hinrichs JW, et al. Prognostic value of CTNNB1 gene mutation in primary sporadic aggressive fibromatosis. Ann Surg Oncol. 2015;22(5):1464-1470. 52 . Smith ZD, Meissner A. DNA methylation: roles in mammalian development. Nat Rev Genet. 2013;14(3):204-220. 53 . Liu P, Shen JK, Xu J, Trahan CA, Hornicek FJ, Duan Z. Aberrant DNA methylations in chondrosarcoma. Epigenomics. 2016;8(11):1519-1525. 54 . Sheffield NC, Pierron G, Klughammer J, Datlinger P, Schonegger A, Schuster M, et al. DNA methylation heterogeneity defines a disease spectrum in Ewing sarcoma. Nat Med. 2017;23(3):386-395. 55 . Mazurowski MA. Radiogenomics: what it is and why it is important. J AmColl Radiol. 2015;12(8):862-866. 56 . Gevaert O, Echegaray S, Khuong A, Hoang CD, Shrager JB, Jensen KC, et al. Predictive radiogenomics modeling of EGFR mutation status in lung cancer. Sci Rep. 2017;7:41674. 1